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Abstract
Background: The fine balance of immunoglobulins (Ig) E, IgG1, IgG4 and IgA in
healthy production is maintained by the interaction of B cells with adaptive and
innate immune response. The regulation of toll-like receptors (TLRs)-driven
innate and adaptive immune effector B-cell response and the role of mammalian
telomeric TTAGGG repeat elements represent an important research area.
Methods: Human PBMC and purified naive and memory B cells were stimulated
with specific ligands for TLR2, TLR3, TLR4, TLR5, TLR7, TLR8 and TLR9 in
the presence or absence of telomeric oligonucleotides. B-cell proliferation, differ-
entiation and antibody production were determined.
Results: TLR9 ligand directly activates naive and memory B cells, whereas TLR7
can stimulate them in the presence of plasmacytoid dendritic cells. Human B cells
proliferate and turn into antibody-secreting cells in response to TLR3, TLR7 and
TLR9, but not to TLR2, TLR4, TLR5 and TLR8 ligands. Stimulation of B cells
with intracellular TLR3, TLR7 and TLR9 induced an activation cascade leading
to memory B-cell generation and particularly IgG1, but also IgA, IgG4 and very
low levels of IgE production. Mammalian telomeric oligodeoxynucleotide (ODN)
significantly inhibited all features of TLR ligand-induced events in B cells includ-
ing B-cell proliferation, IgE, IgG1, IgG4, IgA production, class switch recombi-
nation, plasma cell differentiation induced by TLR3, TLR7 and TLR9 ligands.
Conclusion: B cells require specific TLR stimulation, T-cell and plasmacytoid den-
dritic cell help for distinct activation and Ig production profiles. Host-derived
telomeric ODN suppress B-cell activation and antibody production demonstrating
a natural mechanism for the control of overexuberant B-cell activation, antibody
production and generation of memory.
The fine balance of immunoglobulins (Ig) E, IgG1, IgG4 and
IgA is deviated to exuberant production of allergen-specific
IgE and weak production of IgG4 in allergic individuals (1).
The interaction of the environmental factors including
allergens and microbial components with innate and adaptive
immune system results in the class switch recombination of
immunoglobulins (2). Cells of the innate immunity equipped
with toll-like receptors (TLRs) have an immense capacity to
recognize a diverse spectrum of microorganisms including
bacteria, viruses, fungi and parasites (1–4). While TLR10
ligand is yet to be described in humans, the specific ligands
of TLR1 to TLR9 drive innate and adaptive immune effector
cells towards inflammation and microbicidal activity (3, 4).
TLR1, 2, 4, 5 and 6 are expressed on the cell surface,
whereas TLR3, TLR7, TLR8 and TLR9 have been shown to
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be expressed in the endosomes of cells (3–6). The intracellular
localization of the latter TLRs allows bacteria and virus to
be degraded in the endosomes/lysosomes after engulfment
and phagocytosis in the innate immune cells during infection.
This process is induced by the association of double-stranded
RNA to TLR3, single-stranded RNA to TLR7 and TLR8
and unmethylated CpG motifs containing DNA to TLR9 (4,
7–12). TLR distribution intensity in the immune system cells
and ligands for TLR has a critical role to understand host–
pathogen interactions and the effects on the adaptive immu-
nity. TLR expression shows different aspects in mouse and
human cells, especially in B cells. Mouse B cells proliferate
and differentiate upon LPS and CpG stimulation (13, 14),
whereas human B cells respond to CpG (15) but not to LPS
stimulation (16).
Bacterial DNA contains immunostimulatory CpG motifs
that stimulate dendritic cells, NK cells and B cells and lead
to their proliferation, maturation and secretion of a variety
of cytokines, chemokines and immunoglobulins (2, 17, 18). It
has been reported that suppressive ODN motifs can selec-
tively block CpG-mediated immune activation. Suppressive
motifs are rich in poly ‘G’ or ‘GC’ sequences and are present
in the DNA of mammals and certain viruses. Suppressive
oligodeoxynucleotides (ODNs) expressing arrays of the hexa-
meric TTAGGG repetitive elements patterned after mamma-
lian telomeres (19) have been demonstrated to block
CpG-induced cytokine production in vitro and inhibit
CpG-induced inflammatory reactions such as lethal endotoxic
shock in mice (20).
Therefore, we postulated that a natural inhibitory mecha-
nism mediated by mammalian telomere motifs could help to
restore B-cell homoeostasis. Stimulation of human PBMC
via endosomal-associated TLRs as well as direct activation of
naive or memory B cells with CpG ODN and plasmacytoid
dendritic cell maturation by TLR7 induces polyclonal B-cell
activation, proliferation and IgE, IgA IgG1 and IgG4 pro-
duction suggesting a mechanism of immunological memory.
After class switching in naive B cells, memory B cells and
plasma cells that produce immunoglobulin E (IgE+ cells)
develop through a germinal centre IgE+ intermediate cell
without an IgG1 phase. In addition, cellular IgE memory
resides in IgE+ memory B cells, and IgG1+ memory B cells
are not an important source of IgE memory (21). Here, we
demonstrate that a synthetic analogue of mammalian telo-
meres containing four repeats of TTAGGG motif suppresses
B-cell activation, proliferation and antibody production
induced directly or indirectly by TLR3, TLR7 and TLR9
ligands.
Materials and methods
Isolation and purification of cells
PBMCs were obtained from heparinized whole blood or
buffy coats from healthy individuals by Ficoll (Biochrom
KG, Berlin, Germany) density gradient centrifugation. Cells
were washed three times and resuspended in RPMI 1640
medium supplemented as previously described (22). B cells
were purified by magnet-activated cell separation after label-
ling of cells with anti-CD19 microbeads (MACS; Miltenyi
Biotec AG, Bergisch Gladbach, Germany). The purity of B
cells was >94% as assessed by flow cytometric analysis of
cells stained with ECD-labelled anti-CD19 mAb (Immuno-
tech; Beckman Coulter, Marseille, France).
Following B-cell staining with anti-CD19 mAb (Dako AG,
Baar, Switzerland) and anti-CD27 mAb (Immunotech, Beck-
man Coulter), naive and memory B cells were double sorted
by flow cytometric sorter (FACS Vantage SE; Beckton Dick-
enson, Pharmingen, Basel, Switzerland). The purity of naive
and memory B cells was >99% as assessed by flow cytometric
analysis of cells stained with PE-labelled anti-CD19 mAb
(Dako AG, Baar, Switzerland), PC5-labelled anti-CD27 mAb
(Immunotech, Beckman Coulter) and FITC-labelled anti-
CD123 mAb (Miltenyi Biotec AG). Naive B cells contained
<0.1% CD27+ memory B cells and <0.5% plasmacytoid den-
dritic cells, and memory B cells contained <1% CD27 B
cells and <0.9% plasmacytoid dendritic cells.
Plasmacytoid dendritic cells were isolated from PBMC by
positive selection using antibodies against BDCA-4 coupled to
microbeads (FcRc) blocking reagent and the AutoMACS mag-
netic separation system (Miltenyi Biotec, Bergisch Gladbach).
Cultures of PBMC and B cells
Ligands for TLRs were Pam3-Cys-Ser-(Lys)4 for TLR2 (Cal-
biochem AG, Laufelfingen, Switzerland), poly(I:C) for TLR3
(Amersham Biosciences, Lausanne, Switzerland), E. Coli-
derived lipopolysaccharide for TLR4 (Sigma Chem. Co., Buc-
hs, Switzerland), flagellin for TLR5 (Calbiochem AG), 3M-001
for TLR7 (3M Pharmaceuticals, Minneapolis, MN, USA),
3M-002 for TLR8 (3M Pharmaceuticals) as described previ-
ously (23) and CpG2006 for TLR9 (Microsynth GmbH, Balg-
ach, Switzerland). Phosphorothioate-modified ODNs were
synthesized at the Microsynth GmbH, Balgach, Switzerland.
Sequences of the phosphorothioate ODNs used were as fol-
lows: CpG2006 ODN: 5′-TCGTCGTTTGTCGTTTTGTCG
TT-3′, control for immunostimulatory ODN (non-CpG):
5′-ATGCACTCTGCAGGCTTCTC-3′, telomeric ODN:
5′-TTAGGGTTAGGGTTAGGGTTAGGG-3′, base scram-
bled ‘control ODN’: 5′-ACATAGTCTCTCTCTAGTCAG
TCT-3′. All reagents and ODNs used in this study contained
<0.1 U/mg endotoxin. There was no cell toxicity of the ODN
as investigated by annexin-V and 7-amino actinomycin D
staining after 48 h up to 10 lM doses (24). Recombinant IL-2
and IL-4 were from Novartis, Basel, Switzerland. Soluble
CD40 ligand (sCD40L) was obtained from the transfected cell
line 8-40-1 (sCD40L-CD8-a fusion protein; Institute for
Immunology, Basel, Switzerland) (25).
5 9 105 PBMCs or purified naive or memory B cells were
stimulated in 500 ll with different TLR ligands in 48-well
plates (Costar Corporation, Cambridge, MA, USA). After ini-
tial experiments for dose optimization, Pam3-Cys-Ser-(Lys)4
was used at 0.6 lM, poly(I:C) at 25 lg/ml, lipopolysaccha-
ride at 100 ng/ml, flagellin at 1.8 lM, 3M-001 and 3M-002
at 1 lM, CpG2006 and control ODN at 1 lM. IL-2 was
used at 4 ng/ml, IL-4 was 25 ng/ml, sCD40L was at 20% v/v
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as supernatant (26), IFN-a and IFN-b were 100 ng/ml where
indicated. TTAGGG telomeric ODN and control ODN were
used in titrated doses and 1 lM in other experiments. Cells
were pulsed with 1 lCi/well [3H] thymidine (Dupont and
NEN Life Science Products, Basel, Switzerland) for the last
8 h of incubation, and [3H] thymidine incorporation was per-
formed at day 3 for transformed B cells and T cells and at
day 5 for primary B cells.
Analysis of B-cell activation and proliferation by FACS,
determination of IgG1, IgG4, IgA and IgE by ELISA,
Ig-secreting cells by ELISPOTs and immunoglobulin mRNA
transcription determination by real-time PCR (refer to Meth-
ods in the Supporting Information).
Statistical analysis
Results are shown as mean  SD. Nonparametric statistical
comparison between groups was performed by Mann–Whitney
U-test. The number of donors indicated in the figure legends
includes all donors analysed in the relevant experiment.
Results
TLR3, TLR7 and TLR9 stimulations induce B-cell
proliferation, which is suppressed by telomeric ODN
Activation and clonal expansion of B cells is an essential
event for immunoglobulin production. To investigate the role
of different TLRs on human B-cell activation, proliferation
and different isotypes of immunoglobulin production, we
used different TLR-stimulated PBMCs, purified B cells and
naive and memory B-cell subsets isolated from peripheral
blood of healthy humans. First, PBMCs were stimulated with
ligands of TLR2, TLR3, TLR4, TLR5, TLR7, TLR8 and
TLR9 in the presence of IL-2 for 5 days. [3H] thymidine
incorporation was determined after 5 days. Ligands for
TLR3, TLR7 and TLR9 induced significant cell proliferation.
Human telomeric ODN significantly suppressed TLR3-,
TLR7- and TLR9-mediated PBMC proliferation in a dose-
dependent manner (Fig. 1A) reaching up to 60%, 90% and
80% inhibition at 5 lM doses, respectively (Supporting
Information Fig. S1A). For comparison, control ODN did
not show significant suppressive activity (Fig. S1B). Telomeric
ODN, 1 lM, significantly suppressed PBMC proliferation
stimulated by TLR3, TLR7 and TLR9 ligands (Fig. 1B).
The next step was to identify the proliferating cell type within
PBMC upon TLR3, TLR7 and TLR9 stimulations. Interest-
ingly, stimulation of TLR3, TLR7 and TLR9 induced CD19+
B cell, but not CD4+, CD8+ T-cell or CD16+ NK cell prolifer-
ation (Fig. 2). Mammalian telomeric ODN significantly inhib-
ited B-cell proliferation induced by TLR3, TLR7 and TLR9.
The exact identification of B-cell subsets is instrumental to
understand their dynamics under physiological and pathological
conditions. Human memory B cells are currently identified
according to the expression of CD27, which is absent on naive
B cells. It was shown that naive and memory B cells respond
differently to the same TLR ligand especially to CpG (16, 27,
28). In addition, it was recently demonstrated that under cer-
tain conditions including cell–cell contact and appropriate
cytokine and growth factor support, CD27 na€ıve B cells
increase TLR9 expression, proliferate in response to CpG
stimulation without B-cell receptor signalling and differentiate
into plasma cells (27). To specifically differentiate the prolifer-
ative responses of naive and memory B cells induced by
TLR3, TLR7 and TLR9 stimulation, highly purified
CD19+CD27 naive and CD19+CD27+ memory B cells were
stimulated. Upon TLR9 stimulation, na€ıve and memory B
cells proliferated without the help of type 1 IFNs or plasmacy-
toid dendritic cells (Fig. 3A, B). TLR3 and TLR7 ligands,
however, failed to directly induce the proliferation of highly
pure naive and memory B cells. TLR7 stimulated a small frac-
tion of na€ıve B cells in the presence of plasmacytoid dendritic
cells, and memory B cells in the presence of IFN-a, IFN-b or
plasmacytoid dendritic cells. Again, mammalian telomeric
ODN significantly suppressed TLR7- and TLR9-ligand-
induced CD19+CD27 naive and CD19+CD27+ memory
B-cell proliferation independent of the combination with IFN-
a, IFN-b and the presence of plasmacytoid dendritic cell help.
These data demonstrate direct and indirect activation and
clonal expansion of B cells by TLR stimuli. TLR3 and TLR7
ligands cannot directly stimulate naive and memory B cells.
In a mixed population of PBMC, when they coexist with the
T-cell help or dendritic cells, they become capable of B-cell
stimulation. As a strong stimulator for B cells, CpG induces
direct activation of memory and a fraction of naive B cells.
TLR7 stimulates B cells in the presence of IFN-a, IFN-b
secreted by the plasmacytoid dendritic cells.
Regulation of class switch recombination and IgE, IgG1,
IgG4, IgA production by TLR3, TLR7, TLR9 ligands and
telomeric ODN
B cells are continuously exposed to substances that stimulate
the innate immune response from commensal flora bacteria
in respiratory and gastrointestinal mucosas and they produce
immunoglobulins against pathogens. After demonstration of
the difference in TLR3-, TLR7- and TLR9-ligand-induced
direct or indirect B-cell proliferation, we examined the effects
of these ligands on AICDA mRNA expression and immuno-
globulin synthesis by B cells and PBMC as well as the role of
IL-2, IL-4 and sCD40L stimulation.
PBMCs were stimulated with ligands for TLR3, TLR7 and
TLR9 in the presence and absence of telomeric ODN and
control ODNs. IL-2, IL-4 and sCD40L were used to mimic
T-cell help and promote B-cell clonal expansion. IgE, IgG1,
IgG4 and IgA were measured on day 5 cell lysates (as
mRNA) and day 12 culture supernatants (Fig. 4A, B, C).
IgE antibody synthesis and Ie-Ce RNA transcripts expression
were induced by TLRs in combination with IL-4 and
sCD40L, but not induced with IL-2 and sCD40L in healthy
individuals (data not shown).
As observed in B-cell proliferation, the profiles of immuno-
globulin production showed differences in PBMC and puri-
fied B cells (Fig. 4A, B and Fig. S2). In PBMC, stimulation
via TLR3, TLR7 and TLR9 even in the absence of IL-2
induced IgG1, IgG4 and IgA in detectable quantities. IL-2
Allergy 68 (2013) 593–603 © 2013 John Wiley & Sons A/S. Published by Blackwell Publishing Ltd 595
Sackesen et al. TLR-induced B-cell activation is suppressed by telomeric ODN
significantly increased the synthesis of IgG1, IgG4 and IgA
stimulated with TLR3, TLR7 and TLR9 ligands. Stimulation
of cells with sCD40L had no significant effect on the produc-
tion of immunoglobulins in the absence of IL-2, whereas
IL-2 and sCD40L combination boosted IgG1 levels, and they
had no additional contribution to the induction of IgG4 and
IgA. Increased expression of Ic-Cc1, VHDJH-Cc4 and Ia1/2-
Ca1/2 RNA transcripts for IgG1, IgG4 and IgA in IL-2 and
sCD40L-stimulated PBMC with TLR3, TLR7 and TLR9
verified our results (Fig. 4C). Consistent with the prolifera-
tion studies, telomeric ODN significantly suppressed IgE,
IgG1, IgG4 and IgA secretion and their mRNA expression
independent of the type of TLR ligand in the presence of
IL-4, IL-2 and sCD40L experimental conditions. Upon expo-
sure to the infections or immunizations, activation-induced
cytidine deaminase (AICDA) regulates class switch recombi-
nation and somatic mutation in B cells (29). The expression
of AICDA mRNA was measured after 5 days (Fig. 4D).
Telomeric ODN suppressed the expression of AICDA
mRNA even in PBMC cultured with IL-2 + sCD40L and in
combination with TLR3, TLR7 and TLR9 ligands. Control
ODN did not show any stimulatory or inhibitory effect on
the effect of TLR ligand and telomeric ODN.
We then investigated the effect of TLR3, TLR7 and TLR9
stimulation on antibody-forming cell frequency and whether
it is also inhibited by telomeric ODN. Human PBMCs were
stimulated with TLR3, TLR7 and TLR9 ligands in the pres-
ence of telomeric ODN, IL-2 and sCD40L. Secreted immu-
noglobulins were captured on ELISPOT plates between day
10 and day 11 of cultures. Stimulation via TLR3, TLR7 and
TLR9 significantly increased IgG1, IgG4 and IgA producing
cell frequency (Fig. 5A). Particularly, a relatively high fre-
quency of cells produced IgA after TLR3, TLR7 and TLR9
ligand stimulation. It has to be noted here that secreted
A B
Figure 1 Suppression of TLR-induced human peripheral blood
mononuclear cell (PBMC) proliferation. (A) Suppression of TLR-
induced PBMC proliferation at different concentration of telomeric
oligodeoxynucleotide (ODN). Human PBMCs 106/ml were stimu-
lated with ligands for TLR2 (0.6 lM, Pam3-Cys-Ser-(Lys)4), TLR3
(25 lg/ml, poly I:C), TLR4 (100 ng/ml, lipopolysaccharide), TLR5
(1.8 lM, flagellin), TLR7 (1 lM, 3M-001), TLR8 (1 lM, 3M-002) and
TLR9 (1 lM, CpG2006) in the presence of 4 ng/ml IL-2. Telomeric
ODN was titrated 1:2 starting at 5 lM. To determine proliferative
responses on day 5, cells were pulsed with 1 lCi/well [3H] Thymi-
dine, and [3H] Thymidine incorporation was determined after 8 h.
(B) To further analyse the effects of TLRs and telomeric ODN on
PBMC proliferation, the decrease in CFSE intensity of the cells was
measured by flow cytometry and was used as a measure of the
extent of cell division. Human PBMCs from healthy donors were
labelled with CFSE and stimulated with TLR2, TLR3, TLR4, TLR5,
TLR7, TLR8 and TLR9 ligands in the presence of IL-2 with and with-
out 1 lM of telomeric ODN. TLR-induced cell proliferation stained
by CFSE was determined on day 5 with flow cytometry. Compared
to the unstimulated control group, TLR3, TLR7 and TLR9 ligands
induced significant cell proliferation. Even at higher doses used in
preliminary experiments, TLR2, TLR4 TLR5 and TLR8 ligands did
not induce detectable cell proliferation in human PBMC.
Mean  SD of percentage of proliferating cells in five different
experiments is shown in each histogram. Telomeric ODN signifi-
cantly suppressed cell proliferation in all conditions (P < 0.01).
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immunoglobulins determined in the supernatants by ELISA
represent a cumulative value after 12 days. However, ELI-
SPOTs represent the number of Igs-secreting cells in a certain
time fragment within the course of cultures. Telomeric ODN
significantly suppressed the number of antibody-forming cells
producing IgG1, IgG4 and IgA in all experiments (Fig. 5B)
supporting the data obtained by ELISA.
Suppression of TLR3, TLR7 and TLR9 ligand induced B-cell
differentiation by telomeric ODN
As B cells undergo differentiation towards plasma cells to
produce immunoglobulins, we next aimed to investigate
whether B-cell differentiation is affected by TLR ligands and
whether telomeric ODNs influence B-cell differentiation.
Human PBMCs were double stained with mAbs for CD19,
CD20, CD27, CD38, CD80, CD86, B-cell activating factor of
the TNF family (BAFF) receptor, transmembrane activator
and cyclophilin ligand interactor (TACI) and B-cell matura-
tion antigen (BCMA), which are expressed on B cells depend-
ing on the stage of maturation and activation of the B cell.
Stimulation of PBMC via TLR3, TLR7 and TLR9 in the
presence of IL-2 resulted in a significant increase in the num-
bers of CD19+ B cells. These proliferating B cells expressed
high levels of CD27, CD38 and CD86, demonstrating that a
fraction of proliferating B cells stayed as memory B cells and
Figure 2 Telomeric ODN inhibits B-cell proliferation induced by
TLR3, TLR7 and TLR9. Human PBMCs from healthy donors were
labelled with CFSE and stimulated with ligands for TLR3, TLR7 and
TLR9 in the presence of IL-2 with and without telomeric ODN at
the concentrations indicated in the Fig. 1. Cells were counterstained
with CD19, CD4, CD8 and CD16. The numbers in the boxes repre-
sent the percentage of the proliferating CD19-stained cells. One
representative of four experiments is shown. Telomeric ODN
significantly suppressed CD19+ cell proliferation in all conditions
(P < 0.01). In these experiments, IL-2 consistently induced the
expansion of B cells with these three stimuli in PBMCs. IL-2 also
induced the proliferation of a small fraction of CD4, CD8 and CD16
positive cells. This fraction was more visible in CD4+ cells, how-
ever, was always less than 4.5% of the cells and was not sup-
pressed by telomeric ODN.
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Figure 3 Distinct stimulation of naive and memory B-cell prolifera-
tion by TLR3, TLR7 and TLR9 ligands and suppression by telomeric
ODN. Purified CD19+CD27 naive and CD19+CD27+ memory B
cells were labelled with CFSE to investigate their proliferation by
TLR3, TLR7 and TLR9 stimulation with and without interferon-alpha
(100 ng/ml), interferon-beta (100 ng/ml). Human plasmacytoid den-
dritic cells 4 9 104 were added to na€ıve and memory cells. (A)
TLR9 ligand induce the proliferation of naive B cells. The addition of
plasmacytoid dendritic cells induces the proliferation of na€ıve B cells
by TLR7 ligand. (B) High proliferation rate of memory B cells with
CpG (TLR9 ligand) and moderate proliferation by TLR7 ligand with
IFN-a, IFN-b and the addition of plasmacytoid dendritic cells. The
proliferation rates of na€ıve and memory B cells were suppressed by
telomeric ODN. One representative of three experiments is shown.
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their APC function was increased and some of them matured
to antibody-forming cells (Fig. S3A). The formation of mem-
ory B cells (CD19+CD27+) was significantly inhibited by
telomeric ODN. This was in parallel to suppression of
CD20+, CD86+ and CD38 high+ B cells. The expression
rate of BAFFR, TACI and BCMA showed different patterns
depending on TLR ligand types (Fig. S3B). TLR3 stimula-
tion induced moderate increase in BAFFR, TACI and
BCMA expression; TLR7 stimulation induced TACI and
BCMA expression, and finally, the expression rate of these
B-cell surface markers was not stimulated by TLR9 ligand.
CD27+ and CD86+ B cells development, and TACI+ and
BCMA+ B cells development were suppressed by telomeric
ODN. In contrast, BAFFR-expressing B cells were not sup-
pressed, whereas BAFFR-negative B cells showed a signifi-
cant decrease by telomeric ODN.
Finally to evaluate the plasma cell differentiation in B
cells, we determined surface CD138 expression in parallel to
A
C
D
B
Figure 4 Different requirements in IgE, IgG1, IgG4 and IgA produc-
tion by PBMC with TLR3, TLR7 and TLR9 stimulation and their sup-
pression by telomeric ODN. (A) IgG1, IgG4 and IgA immunoglobulin
synthesis by PBMC 0.5 9 106/ml in 500 ll in 48-well plates was
stimulated with TLR3, TLR7 and TLR9 ligands in the absence or
presence of IL-2 and sCD40L or both. TLR7 and TLR9 ligands and
telomeric ODN were used at 1 lM, and TLR3 ligand was used at
25 ug/ml. IgG1, IgG4 and IgA were measured in day 12 superna-
tants. (B) PBMCs 0.5 9 106/ml in 500 ll in 48-well plates were
stimulated with TLR3, TLR7 and TLR9 ligands in the presence of IL-
4 and sCD40L. IgE was measured in day 12 supernatants by ELISA.
(C) Relative Ie-Ce, Ic-Cc1, VHDJH-Cc4, Ia1/2-Ca1/2 RNA transcripts
for IgE, IgG1, IgG4 and IgA quantified with real-time PCR. The mea-
surements after TLR ligand stimulations were expressed as fold
increase relative to the measurement from unstimulated cells.
Results are representative of four experiments. (D) Suppression of
AICDA mRNA expression by telomeric ODN. PBMCs cultured with
sCD40L + IL-2 were stimulated TLR3, TLR7 or TLR9 ligands alone
or in combination with telomeric or control ODN. mRNA expression
of AICDA was measured after 5 days and its expression is calcu-
lated relative to sCD40L+IL-2. Horizontal bar shows mean (SEM).
Results are representative of four independent experiments.
*P < 0.05.
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CD19+ expression. Surface CD138 expression, which is a
highly and specific marker of plasma cells, was determined in
10 days of PBMC cultures with sCD40L + IL-4 and stimu-
lated by TLR3, TLR7 or TLR9 alone or in combination with
telomeric or control ODN. Stimulation with TLR3 or TLR7
ligands did not induce detectable CD138 expression, but
TLR9 ligand induced its expression at the level of 1.6% of
CD138+CD19+CD3CD16CD147-AAD cells (Fig. 6A).
A CB
Figure 6 Suppression of plasma cell differentiation by telomeric
ODN. PBMCs cultured with sCD40L+IL-4 were stimulated TLR3,
TLR7 or TLR9 alone or in combination with telomeric or control
ODN. (A) Surface CD138 expression was measured by flow cytom-
etry after 10 days culture. CD3CD16CD147-AAD cells were
gated. Stimulation with TLR3 or TLR7 ligands did not induce
detectable CD138 expression. One representative example is
shown as dot plots. (B) Connected dots show percentage of
CD138+ from three independent experiments. (C) Bar graphs show
mean (SEM) percentages of CD138+ cells relative to TLR9 ligand
stimulated cells (set to 100%). Results are representative of three
independent experiments, *P < 0.05.
A
B
Figure 5 The number of TLR3-, TLR7- and TLR9-ligand-induced
IgG1, IgG4 and IgA producing cells decreases by telomeric ODN.
(A) Human PBMCs were stimulated with TLR3, TLR7 and TLR9
ligands with and without telomeric ODN. 3 9 104 PBMCs from
each condition on day 10 were incubated for 24 h. The ELISPOTs
of duplicate wells for each treatment condition on ELISPOT plates
are shown. The numbers of spots in each well is indicated on upper
left corner. (B) Results representative of four independent experi-
ments are shown in the bar graphs. The open bar represent TLR
stimulation and the filled bars represent the addition of telomeric
ODN for IgG1, IgG4 and IgA spots number. *P < 0.05.
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Control ODN did not change the ratio of CD138+CD19+
cells induced by TLR9 ligand. However, telomeric ODN sig-
nificantly suppressed the CD138+CD19+ plasma cell differ-
entiation from B cells induced by TLR9 ligand (Fig 6B, C).
Discussion
The present study demonstrates that TLR3, TLR7 and
TLR9 have distinct stimulatory pathways for B-cell activa-
tion and immunoglobulin production. We demonstrate here
a synthetic analogue of mammalian telomeres suppresses
direct and indirect effects of TLR3, TLR7 and TLR9 ligands
as strong inducers of B-cell proliferation, differentiation and
immunoglobulin production.
Here, we report that in addition to direct stimulation of
B cells via TLR9, stimulation of PBMC via TLR3 and TLR7
indirectly leads to human B-cell proliferation and immuno-
globulin production. Although TLR3, TLR7 and TLR9 are
expressed at the same cellular location, in the endosomes,
their expression rates differ depending on the type of the
cells. In addition to TLR9, human peripheral blood B cells
express high levels of TLR1, TLR6 and TLR10, inter-
mediate levels of TLR7 and low levels of TLR2 and TLR4,
but not TLR3 (28). In the present study, we demonstrate
that stimulation via TLR9 directly activates CD27+ memory
B cells and a fraction of CD27 naive B cells. As shown by
Huggins et al. (27), CpG stimulate not only CD27+ memory
B cells, but CD27 na€ıve B cells under special in vitro
conditions. The present study demonstrates that CpG stimu-
lates highly purified na€ıve and memory B cells and this stim-
ulation is potentialized in the presence of IL-2. Both TLR3
and TLR7 stimuli significantly induced B-cell proliferation
only when PBMCs were stimulated, suggesting that there is
an indirect effect on B cells mediated by other cells or medi-
ators that are present within the PBMC population. The
role of other factors was demonstrated in the present study
by co-cultures of highly purified cells. The role of IL-2 is
demonstrated as one of the essential factors for B-cell prolif-
eration and antibody production by TLR3 and TLR7 stimuli.
It was recently shown that IFN-a released by plasmacytoid
dendritic cells upon stimulation with TLR7 was responsible
for B-cell polyclonal expansion and differentiation into Ig-
producing plasma cells (30). In the present study, the prolif-
eration of purified human B cells, particularly memory B
cells, in the presence of IFN-a, IFN-b and plasmacytoid
dendritic cells induced by TLR7 shows that this stimulatory
effect was mediated via plasmacytoid dendritic cells. The
activation of plasmacytoid dendritic cells by TLR7 results
in the secretion of IFN-a and IFN-b that induce B-cell
activation, proliferation and IgE, IgG1, IgG4 and IgA
production.
Whereas previous studies reported that TLR9 stimulation
by CpG inhibited CD40/IL-4-driven IgE synthesis in human
B cells and IgG1 and IgE synthesis in murine B cells (31,
32). A recent study by Ozcan et al. (33) demonstrates that
murine na€ıve B cells were stimulated by TLR9 ligand with
the cooperation of CD40, TACI and IL-4 produce IgG1 and
IgE. PBMC stimulation via TLR3, TLR7 and TLR9 even in
the absence of IL-2, IL-4 and sCD40L induced IgG1, IgG4
and IgA, in detectable quantities and IgE with the combina-
tion of IL-4 and sCD40L. In contrast to PBMC, purified
human CD19+ B cells produce IgG1, IgG4 and IgA upon
TLR9 stimulation but not TLR3 and TLR7 (Fig. S2). The
production of IgG1, IgG4 and IgA was increased by TLR3
and TLR7 in the presence of IL-2 and this response was
boosted when combined with sCD40L, but sCD40L alone
did not induce additive effect on purified B cells. The pro-
duction of IgE by purified B cells was not induced by TLR3,
TLR7 and TLR9 in the presence of IL-4 and sCD40L con-
trary to the findings in PBMC. The production amount of
IgE by intracellular TLRs is not robust when compared to
IgG1, IgG4 and IgA in PBMC and, moreover, was not
detectable in human purified B-cell cultures. This finding
suggests that intracellular TLR ligands may have a critical
role in changing the balance against IgE and more in the
direction of IgG1, IgG4 and particularly IgA in allergic
diseases (26).
In the present study, we investigated step by step all
aspects of B-cell activation, proliferation, Ig class switch
recombination, AICDA expression and plasma cell differenti-
ation and demonstrated that mammalian telomeric ODN
significantly suppressed all of the features. Suppression of
B-cell activation and Ig production by suppressor ODN rep-
resents an important way for the treatment of diseases
related to B-cell over activation. It can also be used for
allergic diseases. Rituximab, a chimeric mAB to CD20, that
efficiently eliminates circulating and overactive B cells that
have CD20 on their surfaces and is therefore used to treat
diseases characterized by high number of active B cells. A
pilot study was already conducted in extrinsic atopic dermati-
tis characterized by highly elevated concentrations of IgE,
and the early results of treatment with rituximab suggest that
it may be a promising treatment option for patients with
severe atopic dermatitis (34, 35).
Previous studies have demonstrated that suppressor ODN
possessing four repeats of TTAGGG motifs inhibits CpG-
induced inflammation in mice (20, 36, 37). Human telomeres
consist of tandem repetitive arrays of the hexameric sequence
TTAGGG (19). The enzyme telomerase is a cellular ribonu-
cleoprotein responsible for adding telomeric repeats onto the
3′ ends of chromosomes and thus compensates for cell divi-
sion-associated telomere loss (37). Elongation of telomeres
with the telomerase results in an extended lifespan of a cell.
Therefore, it was suggested that the length of the telomere
rather than telomerase itself is responsible for limiting cell
proliferation. Suppressive activity of TTAGGG motifs has
been demonstrated to correlate with the ability of the seq-
uence to form G-tetrads (18). Individual mammalian cells
contain phosphodiester TTAGGG motifs and some of them
including some synthetic analogues are in single-stranded
form. Therefore, it can be expected that high cellular concen-
trations of TTAGGG elements with suppressive capacity can
be released to microenvironment following host cell death or
following cell division. It is possible that self-DNA released
by injured cells could down-regulate TLR-mediated inflam-
mation response.
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Another way to control TLR responses is the TLR
tolerance phenomenon, which is explained by the
unresponsiveness of the immune cells to the same or different
TLR ligands upon the occurrence of repeated or chronic stim-
ulation through TLRs (38). The tolerant state in macrophages
and B cells was associated with reduced NF-jB, MAPK acti-
vation and c-Jun phosphorylation (39). However, B cells may
receive general signals through TLRs and specific signals
through BCR. The prestimulation of B cells with TLR7 may
result in reduced B-cell proliferation and IgM secretion upon
subsequent TLR7 restimulation, but simultaneous BCR sig-
nalling may prevent or reverse TLR7- or TLR9-mediated
TLR tolerance in human B cells. This distinct response of
TLRs and BCR to the TLR7 and TLR9 ligands may be a
potential way to study the effects of telomeric ODNs on B-cell
responses induced by TLR ligands. The TLR9 ligand, which
is nucleic acid sequence, may bind to TLR9 localized in the
endosomes. Telomeric ODNs that are also nucleic acid
sequence too may have a potential to regulate B-cell response
similar to the tolerance phenomenon that takes place by
repeated or chronic stimulation through TLRs.
In both PBMC and B-cell cultures, mammalian telomeric
ODN suppressed TLR3-, TLR7- and TLR9-ligand-induced
B-cell proliferation without regarding direct or indirect stimu-
lation. Whereas the generation of both TACI and BCMA
positive and negative B cells were suppressed, the BAFFR-
expressing B cells were resistant to suppression by telomeric
ODN. Moreover, telomeric ODN significantly suppressed the
proliferation of the antibody-forming cells. These findings
were fully supported by demonstration of significant decrease
in secreted Igs to the supernatants of PBMC and purified B
cells by telomeric ODN. It remains to be elucidated whether
the different levels of B-cell memory and serum antibodies to
different pathogens depend on the amount of cell death and
released telomeric ODN to the microenvironment during
exposure and generation of the immune response.
It has been suggested that environmental stimuli such as
CpG maintain continuous polyclonal memory B-cell activa-
tion, proliferation and differentiation (40). In this way, a
constant level of plasma cells and serum antibodies could
theoretically be maintained throughout a human lifespan.
Our study showed that in addition to CpG, TLR3 and TLR7
ligands have a capacity to induce B-cell activation in PBMC,
which was significantly enhanced by IL-2. These findings
demonstrate that direct or indirect stimulation of human B
cells through endosomal-associated TLRs plays a pivotal role
in polyclonal B-cell activation and immunoglobulin produc-
tion to maintain long-term serological memory in humans.
Suppression of this response by host-derived telomeric ODN
suggests a natural mechanism to overcome hyperactivation of
B cells and hyperproduction of immunoglobulins under
chronic inflammatory conditions. The distinct effects of intra-
cellular TLR3, TLR7 and TLR9 and telomeric ODN on
B-cell activation, proliferation, AICDA expression, Ig class
switch recombination, IgE, IgG1, IgG4, IgA production and
plasma cell differentiation suggest a crucial role for the
immunomodulation of B cell-mediated diseases as well as
allergic inflammation.
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